PAO Group, Inc. PAOG, a holding company focused on alternative patient treatments, confirmed Friday it will launch a CBD Nutraceuticals line of products.
The company will create and sell new CBD nutraceuticals together with Alkame Holdings, Inc. ALKM, which will take on the role of co-packer, and North American Cannabis Holdings, Inc. USMJ whose team will help with distribution services.
PAOG is currently working on a CBD pharmaceutical product called RespRx as therapy for chronic obstructive pulmonary disorder. The product is derived from a patented cannabis extraction method.
CBD Nutraceuticals is expected to generate revenue this year, as the first three products will be launched during the fourth quarter of 2021:
- The first CBD nutraceutical, still in development, will be called CBD Relax-Rx and be used to treat anxiety and depression - a market projected to be worth around $18 billion by 2025.
- The second CBD product from the line, also in progress, is being developed from the company’s current research on the treatment of COPD, although separate from the pharmaceutical market.
- The third CBD nutraceutical being developed in collaboration with EVERx CBD Sports Water, which is owned by Puration, Inc. PURA, will target the sports nutrition market.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Missed the first wave of cannabis investments? Don’t make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
- 47.10% with $GTBIF
- 40.23% with $TCNNF
- 21.50% with $VFF